Notes Payable - Schedule of Notes Payable (Detail) - USD ($)		Sep. 30, 2022	Dec. 31, 2021
Schedule Of Notes Payable [Line Items]
Total Notes Payable		$ 9,794,380	$ 9,188,374
Less: Debt Discount		(1,321,959)	(796,565)
Total		8,472,421	8,391,809
Notes Payable
Schedule Of Notes Payable [Line Items]
Total Notes Payable	[1]	5,600,000	5,600,000
Promissory Note
Schedule Of Notes Payable [Line Items]
Total Notes Payable	[2]	500,000	0
Convertible Notes Payable
Schedule Of Notes Payable [Line Items]
Total Notes Payable	[3]	1,050,000	0
Term Note Payable [Member]
Schedule Of Notes Payable [Line Items]
Total Notes Payable		$ 2,644,280	$ 3,588,374

[1] on August 12, 2021, the note payable was amended to extend the debt to September 30, 2024. It was determined that under ASC 470, the debt amendment was considered a modification.

[2] on February 28, 2022, the Company was obligated to issue 125,000 shares of common stock as further consideration for making this loan to the Company. The shares were issued in April 2022.

[3] on April 4, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with Crom. The SPA includes (a) a Convertible Promissory Note dated April 4, 2022 in the amount of $1,050,000 at 7% interest per annum. This note matures April 4, 2023 (one-year) and is convertible at a conversion price of $1.60 per share; (b) the issuance of 656,250 warrants that mature April 4, 2027, with an exercise price of $1.84 per share; and (c) the issuance of 1,250,000 common shares at $0.40 per share ($500,000), the proceeds of which were paid to The Buckhout Charitable Remainder Trust for the First Payment. In addition, Crom was issued 125,000 common shares as further inducement to enter into the SPA. The Company analyzed the debt instrument with Crom, under ASC 815-10, and determined that the conversion option should be separated from the host debt instrument (i.e., bifurcated) and classified as a derivative liability, along with the value of the warrants as a derivative liability at the inception date of April 4, 2022. The fair value of the derivative liabilities at inception were reflected as a discount on the note, along with an original issue discount of $50,000, and the discount of $93,000 on the 1,250,000 shares of common stock issued to Crom that had a fair value of $593,000 which exceeded the $500,000 paid by Crom that will be amortized over the life of the note (one year). The derivative liability is marked to market each reporting period, and the Company recognized a loss on the change in fair value of the derivative liabilities of $173,000 from April 4, 2022 to September 30, 2022.